|
|
GPI-CCL28 |
|
Vaxjo ID |
322 |
|
Vaccine Adjuvant Name |
GPI-CCL28 |
|
Description |
Chimeric virus-like particles (cVLPs) containing influenza HA antigen and GPI-anchored CCL28, designed to induce long-lasting mucosal immunity against H3N2 viruses. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
chimeric VLPs (cVLPs) containing influenza HA and GPI-anchored CCL28 as antigen and mucosal adjuvant |
|
Structure |
Chimeric virus-like particles (VLPs) containing influenza HA antigen and GPI-anchored CCL28. |
|
Dosage |
Administered intranasally in mice. |
|
Function |
the results suggest that the GPI-anchored CCL28 induces significantly higher mucosal antibody responses, involved in providing long-term cross-protection against H3N2 influenza virus when compared to other vaccination groups. |
| References |
Mohan et al., 2017: Mohan T, Berman Z, Luo Y, Wang C, Wang S, Compans RW, Wang BZ. Chimeric virus-like particles containing influenza HA antigen and GPI-CCL28 induce long-lasting mucosal immunity against H3N2 viruses. Scientific reports. 2017; 7; 40226. [PubMed: 28067290].
|
|
